Zivo Bioscience Joins Russell Microcap® Index
Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
“We are pleased to be added to the Russell Microcap® Index this year. Our inclusion reflects continued interest in our stock along with long- and near-term growth expectations as we evolve and execute on our business strategy. I also look forward to expanding our stock’s exposure to a broader investor audience, including more institutional investors, as a result of ZIVO’s inclusion,” stated
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately
For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
About
About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220627005035/en/
(248) 452-9866 x 130
kmarchiando@zivobioscience.com
LHA Investor Relations
(212) 201-6614
tpatel@lhai.com
Source: